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Abstract
Cherubism is a rare developmental lesion of the jaw that is generally inherited as an autosomal
dominant trait. Recent studies have revealed point mutations in the SH3BP2 gene in cherubism pa-
tients. In this study, we examined a 6-year-old Korean boy and his family. We found a Pro418Arg
mutation in the SH3BP2 gene of the patient and his mother. A father and his 30-month-old younger
brother had no mutations. Immunohistochemically, the multinucleated giant cells proved positive
for CD68 and tartrate-resistant acid phosphatase (TRAP). Numerous spindle-shaped stromal cells
expressed a ligand for receptor activator of nuclear factor kB (RANKL), but not in multinucleated
giant cells. These results provide evidence that RANKL plays a critical role in the differentia-
tion of osteoclast precursor cells to multinucleated giant cells in cherubism. Additionally, genetic
analysis may be a useful method for differentiation of cherubism.
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herubism is a rare developmental lesion of the 
jaw that is generally inherited as an autosomal 
dominant trait.  It is characterized by a proliferation 
of ﬁbrous tissue and a large number of giant cells.  
Cherubism was ﬁrst described as ʻfamilial multilocular 
cystic lesion of the jawʼ by Jones in 1933 [1].  It 
aﬀects all 4 quadrants of the jaw that cause a charac-
teristic round and symmetrically full face in most 
patients.  Cherubism is usually found in children by 5 
years of age,  and the aﬀected mandible and maxilla 
begin to swell.  The clinical alterations typically prog-
ress until puberty,  then stabilize and slowly regress 
[2,  3].
　 In the latest genetic research,  the gene responsible 
for cherubism was discovered.  It is mapped to chro-
mosome 4p16.3 and named SH3BP2 (SH3-binding 
protein) [2].  Point mutations in the SH3BP2 gene 
were demonstrated in 12 of 15 families by Ueki et al.  
in 2001 [4].  All the mutations identiﬁed so far are 
located in exon 9 and result in amino acid substitu-
tions within a 6-amino acid sequence from position 
415 to 420 [2,  4ﾝ7].  However,  recently,  Carvalho et 
al.  described a novel mutation in exon 3 of the 
SH3BP2 in an aggressive case of cherubism [8].  In 
addition,  SH3BP2 is rarely mutated in exon 9 in giant 
cell lesions outside cherubism,  which means that 
cherubism is a separate entity [9,  10].  And recently,  
Ueki et al.  have reported that SH3BP2 is a critical 
regulator of myeloid cell responses to M-CSF and 
RANKL stimulation using a mouse model,  and have 
suggested why the SH3BP2 missense mutation causes 
bone loss and inﬂammation in the patient [11].
　 In this article,  we investigated mutational analysis 
of the SH3BP2 gene,  including CD68,  tartrate-resis-
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tant acid phosphatase (TRAP),  and a ligand for recep-
tor activator of nuclear factor kB (RANKL) immuno-
histochemistry in a Korean child with cherubism.
Case Report
　 A 6-year-old Korean boy was referred to our clinic 
because of his symmetrical painless swelling of man-
dible and maxilla.  At ﬁrst,  his parents noticed the 
full,  round lower contour of his face.  Physical and 
mental development was normal.  No exophthalmos was 
found and his visual activity was normal.  Family his-
tory was absent,  and no other family members had 
characteristic features clinically.
　 Oral examination disclosed no gross abnormalities 
except fusion of the central and lateral incisor on the 
right side of the mandible.  Panoramic radiography 
demonstrated multiple multilocular cystic spaces in the 
bilateral mandible and maxilla.  The mandibular lesions 
were extended to the angles and ascending ramus,  but 
the condyles were not aﬀected.  Three-dimensional 
(3D) CT imaging revealed bilateral multilocular cystic 
lesions in the maxilla and mandible that had a soap 
bubble appearance (Fig.  1).
　 A microscopic examination of the incisional biopsy 
specimen revealed numerous multinucleated giant cells 
together with spindle-shaped ﬁbroblastic cells within 
a ﬁne ﬁbrillar collagenous stroma.  Multinucleated 
giant cells were scattered randomly throughout the 
cellular and ﬁbrous tissue (Fig.  2A).
　 To elucidate the origin of the multinucleated giant 
cells,  we performed immunohistochemical analysis.  
CD68 (clone PG-M1,  Transduction Labaratories,  
Lexinton,  KY,  USA),  TRAP (clone 26E5,  Bio-
genex,  San Ramon,  CA,  USA) and RANKL (clone 
70525,  R&D System,  Minneapolis,  MN,  USA) anti-
body were used as the primary antibodies.  The sec-
tions were stained using the avidin-biotin complex 
(ABC) technique with monoclonal antibodies.  Antigen 
retrieval was performed using a microwave oven for 
20 min (CD68,  TRAP) or autoclave for 5 min 
(TRAP) before exposure to the primary antibody.  The 
peroxidase reaction was developed using diaminoben-
tine.  A Meyerʼs hematoxylin was used as a counter-
stain.  As a result,  the multinucleated giant cells in the 
lesion proved positive for CD68 marker (Fig.  2B).  
Some of the mononuclear cells of the lesion also 
exhibited a mild immunoreactivity.  In addition,  TRAP 
activity was also consistently detected in the multinu-
cleated giant cells.  They contained brownish intracy-
toplasmic granules (Fig.  2C).  Numerous spindle-
shaped stromal cells expressed a ligand for RANKL 
antibody,  but not in multinucleated giant cells (Fig.  
2D).
　 Blood samples were obtained from the patient and 
his younger brother,  his parents with their written 
informed consent for DNA analysis.  Genomic DNA 
was extracted from blood using an AccuPrep® 
Genomic DNA Extraction Kit (Bioneer,  Daejeon,  
Korea).  We analyzed exon 9 because the mutation 
hotspot is located in this region [4].  We used the 
polymerase chain reaction (PCR) to amplify exon 9 of 
the SH3BP2 gene.  Primers for the PCR experiments 
were designed based on the SH3BP2 gene sequence.  
Samples were prepared in a ﬁnal volume of 50 ｻl that 
contained sense (5ʼ-AGGGGAGCAGAGGGTGG-3ʼ) 
and antisense (5ʼ-GGGACACAGAAGCAGGAAG-3ʼ) 
primers and Taq polymerase (TaKaRa,  Japan) under 
a standard buﬀer condition.  The ampliﬁcation condi-
tions of the fragments were as follows: after an initial 
denaturation at 94℃ for 5 min,  samples were ampli-
ﬁed by 35 cycles at 94℃ for 30 sec,  60℃ for 30 sec,  
72℃ for 1 min,  followed by a ﬁnal extension at 72℃ 
for 10min,  and hold at 4℃.  PCR products were 
electrophoresed in a 1.5ｵ (w/v) agarose gel,  visual-
ized under UV light with ethidium bromide staining 
and puriﬁed using an AccuPrep® PCR Puriﬁcation 
Kit (Bioneer,  Daejeon,  Korea).  Isolated PCR prod-
ucts were sequenced on an Applied Biosystems 310 
Genetic Analyzer (Applied Biosystems Inc.,  Foster 
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Fig. 1　 The three-dimensional CT image shows bilateral multi-
locular cystic lesions in the maxilla and mandible.
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City,  CA,  USA).  After sequencing of genomic DNA,  
we found a missense mutation Pro418Arg in exon 9 of 
the SH3BP2 gene of the patient and that of his 
mother (Fig.  3A,  B).  His father and younger brother 
did not have this mutation.
Discussion
　 Though the presence of numerous small vessels 
with large endothelial cells and perivascular cuﬃngs 
has previously been reported,  only a small number of 
blood vessels were found in the present case and there 
was no hemosiderin deposition.  These results made it 
diﬃcult to make a diagnosis of cherubism.  Recent 
genetic advances have been made in relation to 
cherubism with the identiﬁcation of the gene SH3BP2 
[2,  5].  SH3BP2 was initially identiﬁed as a protein 
that can bind to c-Abl via its SH3-binding domain.  It 
is expressed in a number of tissues and considered to 
be a proliferative signal-transducing protein [4].  
SH3BP2 has 13 exons,  but all mutations of SH3BP2 
reported as yet in patients with cherubism occur 
within a 6-amino acid region (amino acid 415ﾝ420) 
encoded by exon 9 [2,  4ﾝ7].  Recent study has 
revealed that there are no mutations in the SH3BP2 
gene in patients with aggressive central giant cell 
granuloma [9,  10].  These results indicate that 
cherubism is a distinct entity,  and we can use this 
genetic analysis for speciﬁc diagnosis of cherubism.  
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Fig. 2　 Microscopic ﬁndings showed numerous multinucleated 
giant cells together with spindle-shaped ﬁbroblastic cells within a 
collagenous stroma (A).  Multinucleated giant cells proved positive 
for both CD68 (B) and TRAP (C).  Numerous spindle-shaped stro-
mal cells expressed a ligand for RANKL antibody,  but not in multi-
nucleated giant cells (D).
Fig. 3　 DNA sequencing chromatogram of the patient and his 
mother shows a missense mutation at codon 418 (CCC－＞CGC),  
creating an amino acid change from proline to arginine. The arrow 
indicates the missense mutation.
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The mutation as described here (Pro418Arg) is a 
well-known mutation hotspot at amino acid numbers 
415 to 420,  allowing us to clearly diagnose the patient 
with cherubism,  not central giant cell granuloma.  To 
our knowledge,  this is the second proven SH3BP2 
gene mutation case of cherubism in Asian populations 
[5].  Though both cases had this point mutation,  the 
patient in the present study showed clinical features of 
cherubism,  but his mother didnʼt show the phenotype.  
The reason we assumed a diagnosis of cherubism is 
that the penetrance of cherubism is higher in men 
(100ｵ) than women (50ﾝ70ｵ) [2,  3,  5].
　 Exactly how mutations in SH3BP2 lead to 
cherubism is not yet known.  The mutation of the gene 
may interfere with signaling.  SH3BP2 binds to a 
variety of cytosolic proteins,  including LAT,  Syk,  
and 14ﾝ3ﾝ3,  and it is an integral component of a sig-
naling pathway that activates NFAT (nuclear factor of 
activated T cell) [12,  13].  A recent study has demon-
strated that this mutation increase NFAT activity 
[14].  NFAT has been proposed to be the master 
transcription factor for osteoclastogenesis,  and 
experimental evident supports a critical role for the 
protein in osteoclast development [10,  14].  We 
therefore believe that this mutation in our patient may 
reinforce the signaling pathways that lead to the 
development and activation of the osteoclast.
　 There have been some indications that multinucle-
ated giant cells have an osteoclastic nature [4,  5].  
According to a recent study of the mouse model of 
cherubism by Ueki et al.  [14],  the SH3BP2 mutation 
is regarded to cause increased myeloid cell responses 
to M-CSF and RANKL stimulation,  and that these 
cells form macrophages with high levels of TNF-ｸ and 
large osteoclasts.  Similarly,  in this study,  these 
multinucleated cells stained positive for CD68 and 
TRAP.  Numerous spindle-shaped stromal cells 
expressed a ligand for RANKL,  but not in multinucle-
ated giant cells.  Based on these ﬁndings and those of 
others,  we suggest that multinucleated giant cells in 
the lesion may be formed from monocyte/macrophage 
precursors.  These precursor cells may diﬀerentiate 
into osteoclasts under the inﬂuence of RANKL-
expressing stromal cells,  so they are believed to be 
osteoclastic in nature.
　 In summary,  we detected the point mutation 
Pro418Arg in the SH3BP2 gene in our patient and 
demonstrated that genetic analysis is a useful method 
in the identiﬁcation of cherubism.  Further investiga-
tions are required to determine how this mutation 
leads to cherubism.
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